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ABSTRACT: Platinum-based chemotherapy is widely used to
treat various cancers, but many patients ultimately relapse due
to drug resistance. We employed phosphoproteomic analysis
and functional assays of the response of SK-OV-3 ovarian
cancer cells to cisplatin as a strategy to identify kinases as
candidate druggable targets to sensitize cells to platinum. A
SILAC-based approach combined with TiO2-based phospho-
peptide enrichment allowed the direct identification of ERK1/
2, p90RSK, and ERBB2 as kinases whose phosphorylation is
regulated by cisplatin. Bioinformatic analysis revealed enrich-
ment in linear phosphorylation motifs predicted to be targets
of p38MAPK, CDK2, and PIM2. All three PIM kinases were found expressed in a panel of 10 ovarian cancer cell lines, with the
oncogenic PIM2 being the most commonly induced by cisplatin. Targeting PIM2 kinase by either biochemical inhibitors or RNA
interference impaired cell growth, decreased cisplatin-triggered BAD phosphorylation, and sensitized ovarian cancer cells to drug-
induced apoptosis. Overexpression of PIM2 triggered anchorage-independent growth and resulted in increased BAD
phosphorylation and cell resistance to DNA damaging agents. The data show that the PIM2 kinase plays a role in the response of
ovarian cancer cells to platinum drugs and suggest that PIM inhibitors may find clinical application as an adjunct to platinum-
based therapies.
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■ INTRODUCTION
The clinical use of platinum compounds was a milestone in the
development of successful cancer chemotherapeutic agents.1
Platinating compounds, including cisplatin, carboplatin, and
oxaliplatin, still constitute part of the front-line treatment
regimen for patients with many types of cancers, including
ovarian, lung, head and neck, testicular, and cervical cancers.
They exert anticancer activity through signaling pathways that
operate in the cytoplasm and in the nucleus. The best
characterized is the formation of platinum−DNA adducts,
which primarily cause intrastrand cross-links that activate the
DNA damage response and the apoptotic pathway, resulting in
cell death.2 Patients usually have a good initial response to
cisplatin-based chemotherapy but later relapse because of the
development of platinum resistance, either intrinsic or acquired.
This markedly lessens the clinical value of platinum
compounds. Several mechanisms account for the platinum-
resistant phenotype and include reduced uptake or increased
efflux of the platinum drugs due to alterations of transporters,
increased glutathione which sequesters the drugs, increased
ability to repair DNA damage, or modulation of apoptosis
signaling pathways.3
Initially, cisplatin-induced DNA lesions trigger the recruit-
ment and activation of the ataxia telangiectasia mutated (ATM)
and of the ataxia and RAD related (ATR) kinases, which in turn
phosphorylate several key proteins that activate the DNA
damage response, leading to cell cycle arrest, DNA repair, or
apoptosis.4 Moreover, cisplatin treatment of cells results in the
activation of various branches of the mitogen-activated protein
kinase system, including those mediated by extracellular signal-
regulated kinases, c-JUN N-terminal kinases, and stress-
activated protein kinases.5,6
We aimed at gaining global insight into the kinases involved
in the response of cancer cells to platinum drugs, as kinases are
amenable and druggable targets for therapy. We used
quantitative phosphoproteomics, which allows the identification
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of both kinase substrates and the activated forms of the kinases
themselves. The kinase substrates were also subjected to
bioinformatic analysis for the prediction of other activated
kinases targeting the identified substrates themselves. The study
of cells treated with cisplatin allowed the identification of PIM2
as a kinase that is induced by the drug and might interfere with
the effectiveness of platinum-based therapies.
■ EXPERIMENTAL PROCEDURES
Cell Lines and Reagents
The SK-OV-3, NIH-OVCAR-3, OAW42, and OV-90 cell lines
derive from serous ovarian carcinomas. IGROV-1, OVCAR-4,
and OVCAR-8 cell lines derive from ovarian carcinomas of
unknown histotype. The OVCAR-5 cell line derives from an
undifferentiated ovarian carcinoma. RMG-1 and TOV-21 G cell
lines derive from clear cell ovarian carcinomas. HCT-116 and
HT-29 cell lines derive from colorectal carcinomas. The HT-29,
OVCAR-4, OVCAR-5, and OVCAR-8 cell lines were from the
NCI-60 collection and obtained from Charles River in 2011.
RMG-1 cell line was purchased from the Japan Health Science
Foundation in 2012. SK-OV-3, OV-90, TOV-21G, NIH-
OVCAR-3, IGROV-1, and HCT-116 cell lines were purchased
from the American Type Culture Collection (ATCC, Manassas,
VA, USA) in 2011. The OAW42 cell line was purchased from
the European Collection of Cell Cultures (Sigma-Aldrich, Saint
Louis, MO) in 2012. All cell lines were grown according to the
manufacturer’s instructions. Stable overexpression of PIM2
kinase was carried out using the specific cDNA in lentiviral
vector pCCLsin.cPPT.PGK.GFP.WPRE that was kindly
provided by Dr. Gagliardi of the Candiolo Cancer Institute.
Cisplatin (CDDP) was purchased from Teva Italia (Teva Italia
S.r.l., Italy). Trabectedin (ET-743) was purchased from
PharmaMar S.A. (Madrid, Spain). Recombinant human
hepatocyte growth factor (rhHGF) was purchased from
Raybiotech Inc. (Norcross, GA). The CDK1/2 inhibitor SU
9516 and the pan-PIM kinase inhibitors SGI-1776 and CX-
6258 were purchased from Calbiochem (EMD Millipore
Corporation, Billerica, MA). Doxycycline was purchased from
Sigma-Aldrich (Saint Louis, MO).
SILAC Labeling
SILAC labeling and sample preparation were carried out as
described.7 Briefly, SK-OV-3 cells were maintained in RPMI
and 10% dialyzed FBS (Dundee Cell Products). To generate
light, medium, and heavy SILAC labeled cells, arginine- and
lysine-free RPMI was supplemented with 200 mg/L L-proline
as well as L-lysine (Lys0) and L-arginine (Arg0), L-lysine-2H4
(Lys4) and L-arginine-U-13C6 (Arg6), or L-lysine-U-
13C6-
15N2
(Lys8) and L-arginine-U-13C6-
15N4 (Arg10) at final concen-
trations of 28 mg/L for the arginine and 146 mg/L for the
lysine amino acids. Approximately 3 × 107 cells were harvested
for each experimental set. All of the experiments were carried
out at 5% FBS, and cells, where indicated, were pretreated for
48 h with rhHGF (100 ng/mL) before exposure to CDDP (20
μM) for 6 and 24 h.
Sample Preparation
Cells were rinsed with PBS and lysed in SDS-containing buffer
(4% SDS, 0.1 M Tris-HCl, pH 7.5). Equal amounts (8 mg)
from each experimental condition were combined for
subsequent phosphopeptide enrichment. Equal amounts (50
μg) from each experimental condition were combined for
subsequent in-gel protein digestion. For pS/pT/pY-peptide
isolation, we used the filter-aided sample preparation (FASP)8
followed by fractionation using strong cation exchange (SCX)
chromatography and TiO2-based phosphopeptide enrichment,
9
as described elsewhere.7
LC−MS/MS and Data Processing
Samples were fractionated by nanoscale C18 high-performance
liquid chromatography (HPLC) on a Waters nanoACQUITY
UPLC system coupled to an LTQ-OrbitrapXL (Thermo
Fisher) fitted with a Proxeon nanoelectrospray source, as
described previously.7 The mass spectrometer acquired full MS
survey scans in the Orbitrap (R = 30 000; m/z range 300−
2000) and performed MSMS on the top 5 multiple charged
ions in the linear quadrupole ion trap (LTQ) after
fragmentation using collision-induced dissociation (30 ms at
35% energy). Full scan MS ions previously selected for MS/MS
were dynamically excluded for 180 s from within a rolling
exclusion list (with n = 1). All spectra were acquired using
Xcalibur software (version 2.0.7; Thermo Fisher Scientific).
Raw MS peak list files from each experimental configuration
were searched against the human IPI database (version 3.77)
using the Andromeda search engine10 and processed with the
MaxQuant software suite (version 1.2.2.5).11 The minimum
required peptide length was set to 6 amino acids, and two
missed cleavages were allowed. Cysteine carbamidomethylation
was set as a fixed modification, whereas oxidation and S/T/Y
phosphorylation were considered as variable modifications. The
initial precursor and fragment ion maximum mass deviations in
the database search were set to 7 ppm and 0.8 Da, respectively.
Peptide and protein false discovery rates were set to 0.01.
Proteins with at least one peptide unique to the protein
sequence were considered as valid identifications.
Cluster Analysis of Shortlists and Gene Ontology (GO)
Terms
GProX was used to analyze the data set produced by
MaxQuant.12 SILAC ratios were log2-transformed and sub-
jected to unsupervised clustering based on the fuzzy cmeans
algorithm.13 The data was grouped in 6 clusters (fuzzification
value set = 2; regulation threshold = ±0.58; 100 iterations of
the algorithm performed). Bioinformatic information was then
retrieved, through GProX, from the UniProt database, and
possible enrichment of biological features in the 6 clusters was
assessed (specifically, GO molecular function and GO
biochemical processes annotations, plus the frequency of
protein domains within the Pfam_UniProt database). For the
identification of over-represented GO terms, a binomial
statistical test was used with a Benjamini and Hochberg p-
value threshold set at 0.05 (minimum number of occurrences of
the GO term in the cluster = 2; background = 0; lowest
hierarchical rank = 2). For the enrichment of Pfam annotated
protein domains, the Fischer’s exact test was employed with a
Benjamini and Hochberg p-value threshold set to 1.0.
Linear Kinase Motif Analysis
Phosphopeptides with a phosphorylation localization proba-
bility >0.75 (class 1 sites) were analyzed for common motifs
and their putative regulatory kinases. Sequence windows
comprising ±6 amino acids adjacent to the phosphosite were
extracted from the data set. A partially degenerate amino acid
code was used as described14 to group Arg and Lys, Glu and
Asp, and nonphosphorylated Ser and Thr residues. The list was
submitted to Motif-X15 to identify over-represented motifs
versus the IPI human proteome (occurrence limit = 1% of
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submitted sequence windows, p-value threshold = 1 × 10−6). In
parallel, the full protein sequence and phosphosite for all class 1
phosphopeptides were submitted to NetworKIN v2.046 to
identify putative kinase regulators of these sites.16 We extracted
the subset of phospho-proteins that were significantly
responsive to CDDP. Proteins were grouped according to
their motifs identified by Motif-X, and the percent of the total
within each group putatively regulated by each kinase was
calculated and plotted as a heatmap. To indicate the overall
regulation of sites associated with each motif, average CDDP
ratios were normalized by assigning the maximum observed
increase in phosphorylation a value of 1 and the maximum
decrease a value of −1.
Western Blot Analysis
Western blot analysis was carried out as described.17 The
mouse monoclonal anti-vinculin and rabbit polyclonal anti-P-
BAD (Ser155) were from Sigma-Aldrich (Saint Louis, MO).
The mouse polyclonal anti-P-Erk1/2 (Thr202/Tyr204), rabbit
monoclonal anti-P-ERBB2 (Tyr1221/Tyr1222), anti-PIM1,
anti-PIM2, anti-PIM3, anti-P-BAD (Ser112), anti-BAD, anti-
Erk1/2, anti-c-Myc, rabbit polyclonal anti-P-p38 MAPK
(Thr180/Tyr182), rabbit polyclonal anti-ERBB2, anti-p38
MAPK, anti-cleaved PARP (Asp214), anti-P-Stat3 (Tyr705)
and anti-Stat3 were all obtained from Cell Signaling
Technology (Beverly, MA). Mouse monoclonal anti-γH2A.X
(Ser139) was obtained from Millipore (EMD Millipore
Corporation, Billerica, MA). Bound antibodies were detected
using the appropriate peroxidase-conjugated secondary anti-
body and revealed by enhanced chemiluminescence (Pierce,
Rockford, IL).
Quantitative PCR and Cloning
Quantitative PCR was carried out as described.18 Primer sets
used were as follows: PIM1 FW: TTCGGCTCGGTC-
TACTCAGG, RV: TTAGGCAGCTCTCCCCAGTC; PIM2
FW: ACTCCAGGTGGCCATCAAAG, RV: TCCATA-
GCAGTGCGACTTCG; PIM3 FW: CACTGCCACAGC-
TGCGG, RV: CGCACCCGAACCGAAGT; cyclophilin A
FW: CATCCTAAAGCATACGGGTCC, RV: TTCTTGC-
TGGTCTTGCCATTC. PCR cycling conditions were as
follows: 30 s at 95 °C 30, 5 s at 95 °C followed by 15 s at
60 °C (40 cycles), 30 s at 95 °C, 10 s at 65 °C plus 10 s at 0.5
°C (60 cycles: melting curve). Total cellular RNA was isolated
using the SV total RNA isolation kit (Promega, Fitchburg, WI).
To quantify the expression levels of each PIM gene, equal
amounts of cDNA were synthesized using the Moloney murine
leukemia reverse transcriptase (Promega, Fitchburg, WI) and
mixed with SsoFast EvaGreen Supermix (Bio-Rad, Hercules,
CA) and 300 mM of each of the respective forward and reverse
primers. Quantitative real-time PCR was done on a MyiQ
thermal cycler (Bio-Rad, Hercules, CA). Each target gene’s
expression was evaluated using a relative quantification
approach, with cyclophilin A (GenBank accession
NM_021130) as an internal reference. Drugs were used at
the indicated doses, and RNA was extracted from each time
point for the indicated time.
PIM2 cDNA was amplified starting from cDNA of SK-OV-3
obtained as above. The primers used were as follows: FW:
GGGGATCCCCCGGGCTGCAGATGTTGACCA-
AGCCTCTACAGGGGCCTC and RV: GAGGTTGAT-
TGTCGACTTAGGGTAGCAAGGACCAGGCC. The PIM2
cDNA was cloned into the pCCLsin.cPPT.PGK.GFP.WPRE
lentiviral vector, after plasmid linearization with PstI and SalI
using the in-fusion HD EcoDry cloning plus according to the
manufacturer’s instructions (Clontech Laboratories, Inc., CA).
The GFP cassette was removed from the vector after digestion
with XhoI.
RNA Interference
Stable silencing of PIM2 was achieved using the PIM2-specific
human TRIPZ lentiviral (LV)-inducible shRNA (clone
V2THS_77585; Open Biosystems, Huntsville, AL).
Cell Transduction with Lentiviral Vectors
Cells were transduced using second-generation lentiviral
vectors, whose stocks were produced by transient transfection
of 293T cells with the packaging plasmid pCMV-deltaR8.74,
the envelope plasmid pMD2G-VSVG, and the respective
transfer gene carrying vector. Serial dilutions of freshly
harvested conditioned medium were used to infect 105 cells
in a 6-well plate in the presence of polybrene (8 μg/mL).
Control cells were generated by transduction with the same
empty lentiviral vector.
Apoptosis assay
Caspase activation was determined by labeling cells with anti-
active caspase-3 antibody (BD PharMingen, San Diego, CA)
followed by a PE-conjugated goat anti-rabbit Ig (BD
PharMingen, San Diego, CA). Cells were fixed and
permeabilized with BD Cytofix/Cytoperm (Becton Dickinson,
Franklin Lakes, NJ) according to the manufacturer’s
instructions. Apoptosis was also measured by staining cells
with allophycocyanin (APC)-conjugated Annexin V (Bender
MedSystems, Burlingame, CA) and propidium iodide (Invi-
trogen, Eugene, OR), which allows detection of phosphati-
dylserine (PS) exposure on the cell surface and the loss of
plasma membrane integrity, respectively. The samples were
analyzed on a CyAN-Adp flow cytometer (Dako, CO). Data
acquisition was performed using Summit software (Dako, CO).
Soft Agar and Cell Viability Assay
SK-OV-3 (3000 cells/well) and OVCAR-8 (2000 cells/well)
cells were seeded in triplicate in 6-well plates on a 0.5%
SeaPlaque agar layer (Lonza, Walkersville, MD). The plates
were incubated for 4 and 2 weeks for SK-OV-3 and OVCAR-8
cell lines, respectively. Colonies were stained with MTT salts
(Sigma-Aldrich, Saint Louis, MO), photographed, and counted
using NIH ImageJ (W. Rasband, NIH) software. Three
independent experiments were performed.
Viability assay of ovarian cancer cells treated with the
indicated drugs for the indicated amounts of time was
determined using the CellTiterGlo proliferation kit (Promega,
Fitchburg, WI) according to the manufacturer’s protocol.
Statistical Analysis
Statistical analysis of the data was performed using ANOVA
(Microsoft Excel; Microsoft, Redmond, WA, USA).
The Cancer Genome Atlas Analysis
Using the cBioPortal,19 mutations and copy number alterations
(CNA) of the PIM2 gene in ovarian serous cystadenocarcino-
ma samples studied by the The Cancer Genome Atlas Network
were analyzed (http://www.cbioportal.org/public-portal/index.
do?cancer_study_id=ov_tcga&genet ic_profi le_ids_
PROF ILE_MUTAT ION_EXTENDED=o v_ t c g a _
muta t ions&genet i c_profi l e_ ids_PROFILE_COPY_
NUMBER_ALTERATION=ov_tcga_gistic&genetic_profile_
ids_PROFILE_MRNA_EXPRESSION=ov_tcga_rna_seq_
v2_mrna_median_Zscores&Z_SCORE_THRESHOLD=2.
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0&RPPA_SCORE_THRESHOLD=2.0&data_priority=
0&case_set_id=ov_tcga_all&case_ids=&gene_set_choice=
user-defined-list&gene_list=PIM2&clinical_param_selection=
null&tab_index=tab_visualize&Action=Submit) and compared
to alterations found in all cancer types (http://www.cbioportal.
org/public-portal/cross_cancer.do?cancer_study_id=
a l l&gene t i c_profi l e_ ids_PROFILE_MUTATION_
EXTENDED=ov_tcga_mutations&genetic_profile_ids_
PROFILE_COPY_NUMBER_ALTERATION=ov_tcga_
g i s t i c& g e n e t i c _ p r o fi l e _ i d s _ PROF I LE_MRNA_
EXPRESSION=ov_tcga_rna_seq_v2_mrna_median_
Zscores&Z_SCORE_THRESHOLD=2.0&RPPA_SCORE_
THRESHOLD=2.0&data_priority=0&case_ids=&gene_set_
choice=user-defined-list&gene_list=PIM2&clinical_param_
se l ec t ion=nu l l&tab_ index= tab_v i sua l i z e&Act ion=
Submit#crosscancer/overview/0/PIM2).
Figure 1. (A) Schematic workflow of the triplexed configuration of the experiments showing the purification modes both for proteomic and
phosphoproteomic analysis. (B) Scatter plot showing how the abundance of the phosphosites identified in the TiO2 was modulated by CDDP and
by the combined treatment HGF + CDDP (HGF, 100 ng/mL for 48 h; CDDP, 20 μM for 24 h). (C) Number of phosphosites identified in the
TiO2 samples that were significantly over- and under-represented following treatment with CDDP (20 μM) for 6 and 24 h, respectively. (D)
Percentage of pS, pT, and pY carrying peptides identified following phosphopeptides enrichment. (E) List of over-represented linear
phosphorylation motifs extracted from the set of phosphopeptides using Motif-X software (left panel). The number (n) of phosphopeptides
matching each motif is indicated. Matrix shows the candidate kinases for these motifs, predicted using NetworKIN. The right panel shows the
average response associated with each motif in response to CDDP treatment.
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■ RESULTS
SILAC-Based Phosphoproteomic Analysis of Ovarian
Cancer Cells Treated with CDDP
We used SILAC (stable isotope labeling by amino acids in cell
culture) in combination with high-resolution mass spectrom-
etry20 to study the dynamic response of the phosphopeptide
network to cisplatin in ovarian cancer cells. We studied the
proteomic and phosphoproteomic profiles of the p53-defective
SK-OV-3 ovarian cancer cells, which are described as being
partially resistant to cisplatin (CDDP) treatment with an IC50
of about 13 μM.21,22 We previously showed that long-term (72
h) treatment with 10 μM CDDP induced the apoptotic death
of approximately 30% of cells and that long-term pretreatment
with hepatocyte growth factor (HGF) increased cell suscept-
ibility to CDDP-induced apoptosis.23 Thus, we treated SK-OV-
3 cells, labeled to equilibrium with distinct isotopic forms of
Table 1. Lists of the Top 50 Up- (Left) and Downregulated (Right) Phosphosites Following 24 h CDDP Treatment (20 μM) of
SK-OV-3 Cells
gene symbol phosphorylation position SILAC ratio M/L gene symbol phosphorylation position SILAC ratio M/L
H2A.X 140 12.619 HNRPLL 68 0.032321
TMPO 433 11.512 ERBB2 1054 0.052858
S100A13 32 10.303 SRGAP1 932 0.077862
NOP56 563 9.4318 LASP1 104 0.082726
RPS20 40S 9 9.3445 SEPT9 49 0.084763
TRIM28 473 9.1525 SMAD2 8 0.11839
HIST1H1C 36 8.492 SQSTM1 269 0.13252
HMGA1 39 8.0107 BAT2 782 0.14
HMGN1 7 8.0019 AGFG1 177 0.18297
GTF2I 784 7.8764 TMPO 306 0.18436
SH3GL1 298 7.7634 LMNA 19 0.19248
RANBP2 1509 7.5123 LMNA 22 0.19248
RTN4 107 7.4245 BAT2L2 2675 0.19379
HIST1H1E 37 7.131 ADD1 617 0.19828
PTRF 167 6.741 H2AFY 129 0.20294
PSMA5 56 6.729 MAP7D1 399 0.20692
SRRM1 781 6.6446 ELAVL1 229 0.21122
VIM 73 6.6358 MAP1B 2271 0.21161
HMGA1 44 6.4513 CLTC 394 0.21606
SNX1 188 6.3006 PPP1R13L 280 0.22523
PPIG 696 6.2914 MAP4 2218 0.23035
CLTA 105 6.2781 AHNAK 637 0.23084
PTRF 169 6.257 OCIAD1 113 0.23325
HCFC1 666 6.2518 SRGAP1 906 0.23534
MAP1B 561 6.1645 LARP4B 732 0.23974
PPP1R12A 299 6.1381 LARP4B 736 0.23974
PNN 66 6.114 PARP4 1335 0.24138
AHNAK2 1112 6.1124 ZDHHC5 398 0.24958
BAD 118 5.6775 HNRNPA1 2 0.25334
GIGYF2 223 5.2316 AHNAK 5739 0.25642
PPP1R12A 507 5.2301 NCL 121 0.26202
VPS26B 304 5.1493 RALY 119 0.26455
EPB41L2 598 5.0998 PPP1R1B 75 0.26459
PHF3 567 5.0823 PSIP1 141 0.27333
PHF3 574 5.0823 SPTAN1 1031 0.27485
SF3B2 343 4.8012 ERBB2 1078 0.28102
STMN1 38 4.7945 ERBB2 1083 0.28102
AHNAK 3426 4.5956 SEC61B 7 0.29316
LMNB1 20 4.5651 PDLIM5 111 0.29364
PTRF 300 4.5576 MAP4 375 0.29573
UGDH 476 4.4537 SEC61B 17 0.29589
NUCKS1 54 4.3301 NUCKS1 179 0.30374
AHNAK2 5175 4.2008 MAP2 1649 0.30471
AHNAK 2397 4.0703 SPAG9 203 0.30632
RAI14 252 4.0435 SPTAN1 1029 0.30667
CLIP1 348 4.0253 AHNAK 5749 0.31337
MAPK1 185 3.9175 HIST1H1D 18 0.31365
TNKS1BP1 1385 3.858 SEPT9 82 0.31463
DENND5B 868 3.8571 ERBB2 1103 0.3183
AHNAK 1452 3.8524 DDX21 89 0.31865
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arginine and lysine, with CDDP for 6 and 24 h, with and
without HGF pretreatment (Figure 1A). Then, we carried out
the proteome and phosphoproteome analyses according to the
workflow indicated in Figure 1A. Phosphopeptides were
purified and then analyzed using liquid chromatography
coupled with tandem mass spectrometry (LC−MS/MS).9 In
parallel, in-gel digestion of proteins resolved by SDS-PAGE was
performed to investigate the CDDP and CDDP + HGF
response of the whole proteome.
The scatter plot in Figure 1B shows that CDDP dictated a
clear phosphoproteomic signature in SK-OV-3 ovarian cancer
cells that was only minimally fine-tuned by HGF coapplication.
In fact, only very few phosphopeptide changes were associated
with the addition of HGF to CDDP. Thus, we focused our
attention on the response of ovarian cancer cells to the drug
alone.
In our phosphopeptide data set, we identified over 1000
phosphorylation sites belonging to 445 proteins in both SK-
OV-3 cells treated with CDDP for 6 h and in those treated for
24 h (Supporting Information Table S1). Figure 1C shows the
number of the detected phosphosites that were considered
either CDDP upregulated or CDDP inhibited, as defined by
>1.5 or <0.67 fold change in enrichment, respectively, following
stimulation with the drug for 6 and 24 h. Changes in cellular
phosphorylation status were evident at 6 h but showed
enhancement with a longer time of treatment.
Figure 2. (A) Western blot analysis showing that the PIM kinases are expressed in a panel of 10 ovarian cancer cell lines. HT-29 and HCT-116
colorectal cancer cells were used as positive controls. Notably, alternative initiation sites have been reported for PIM1 and PIM2, which allow for the
generation of different proteins of 34 and 40 kDa and 34, 37, and 40 kDa, respectively. The two longest PIM2 isoforms (37 and 40 kDa) are visible
in this and in the subsequent blots. (B) Quantitative real-time PCR (qPCR) showing the expression of PIM1, PIM2, and PIM3 genes in response to
24 h CDDP treatment in a panel of ovarian cancer cell lines. Different concentrations of CDDP were used according to the different drug
susceptibility of each cell line: 20 μM for NIH-OVCAR3 and SK-OV-3, 10 μM for IGROV-1, and 5 μM for OVCAR4. (C) Time-course analysis by
qPCR showing that only PIM2 expression was significantly induced following shorter CDDP (20 μM) treatment of SK-OV-3 cells. (D−F) Western
blot analysis showing that CDDP treatment induced PIM2 protein expression (D−F) and BAD phosphorylation at S75 and S118 (D) in ovarian
cancer cells. SK-OV-3 (D), OVCAR-8 (E), and OVCAR-4 and IGROV-1 (F) cells were exposed to the indicated concentrations of CDDP (μM) for
the indicated time (h). (G) SK-OV-3 cells were exposed to trabectedin (ET743 0.5 nM) for the indicated time (h). The phosphorylated form of
histone H2A.X (γH2A.X) is shown as a measure of DNA damage. The blots were reprobed with vinculin antibody to confirm equal loading.
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Figure 1D shows the percentage of phospho-serine/
phospho-threonine/phospho-tyrosine (pS/pT/pY) carrying
peptides identified in the data set corresponding to both time
points.
The analysis of all peptides (7216) from the in-gel separation
reveals a substantive change in levels for only 10 out of 718
proteins following 24 h CDDP treatment (Supporting
Information Table S2). This suggests that changes in
phosphopeptides are primarily due to specific activity of
phosphorylation rather than protein abundance.
Among the phosphosites upregulated by CDDP (Table 1),
direct targets of ATM/ATR were identified. Because it is
known that CDDP-induced DNA damage activates these
kinases, their targets were considered as a positive control.
Indeed, the most upregulated phosphosite in the 24 h
treatment data set was serine 139 of the histone H2A.X.
Another identified ATM substrate was serine 473 of the
transcriptional repressor TRIM28/KAP1.24
Among the phosphosites regulated following 24 h CDDP
treatment, some (4%) of them belonged to the following
kinases: ERBB2, MAPK1, p90RSK, CDK12, MARK2, ABL2,
MRCK, MAST2, MAP3K2, PRKAA1, CKB, PFKBF2, MARK3,
MARCKS, PFKL, PI4KB, and MAP2K2. However, for all of the
above kinases except MAPK1, the respective identified
phosphosites did not lie within the activation loop of the
kinase domain, i.e., they cannot be used as a proxy for their
kinase activity.25 Therefore, we also looked for linear
phosphorylation motifs that are over-represented within our
phosphopeptide data set using the Motif-X tool15 (Figure 1E,
left panel). This catalog was then used to generate a list of
candidate kinases that could phosphorylate these motifs using
the NetworKIN algorithm that weights its prediction according
to known protein−protein interactions contained in the
STRING database. As shown in Figure 1E (central panel),
CDK2/CDK3, MAPK 8−10 (also known as JNKs), MAPK
11−14 (also known as p38MAPK isoforms), and the PIM2
kinase were predicted to be the candidate kinases for most of
the pS and pT motifs enriched in our data set. Among the
identified phosphosite-carrying motifs, some were found to be
upregulated following CDDP treatments (Figure 1E, right
panel).
We performed a hierarchical clustering analysis of the
responsive set of proteins/peptides and found 6 groups
corresponding to distinct patterns of response to the time
course of drug treatment (Supporting Information Figure S1A).
The proteins of each cluster were sequentially compared to the
much larger set of unresponsive proteins for the enrichment of
gene ontology (GO) terms relating to molecular functions
(MF) and biochemical processes (BP) as well as for protein
domains within the Pfam_UniProt database, and the results
were displayed as heat maps (Supporting Information Figure
S1B−D). The heat map of the GO BP terms indicated that
cluster 1 is enriched for proteins involved in the progression of
the cell cycle and in the negative regulation of DNA double-
strand break repair. The analysis also suggested that molecules
involved in the Toll-like receptor signaling pathway were
enriched among proteins displaying reduced phosphorylation
upon CDDP treatment and thus belonged to cluster 3.
Figure 3. (A, B) Western blot analysis showing Myc protein expression (A, B) and STAT-3 phosphorylation (B) after the treatment of SK-OV-3 (A)
and OVCAR-5 (B) ovarian cancer cell lines with the specific pan-PIM inhibitor SGI-1776 for 48 h at the indicated doses. (C) Viability of the listed
ovarian cancer cell lines after the treatment with SGI-1776 for 48 h. (D) Viability of the listed cell lines after the treatment with SGI-1776 and
CDDP. Cells were treated for 48 h with different concentrations of SGI-1776 and CDDP according to the drug susceptibility of each cell line, i.e.,
SGI-1776 was 4 μM for SK-OV-3, OVCAR-8, and OVCAR-4 and 2 μM for IGROV-1, OV-90, NIH-OVCAR-3, and OVCAR-5; CDDP was 2 μM
for IGROV-1; 3 μM for NIH-OVCAR-3 and OVCAR-4; 4 μM for SK-OV-3, OV-90, and OVCAR-5; and 8 μM for OVCAR-8.
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Altogether, the phosphoproteome analyses showed that a
number of potentially important kinases are regulated in cells
committed to death by CDDP.
Functional Validation of the Candidate Kinases Regulated
by CDDP in Ovarian Cancer Cell Lines
Our phosphoproteomic analysis suggested that a number of
kinases might play a role in the response of cancer cells to
CDDP. The possible role of ERBB2, ERK1/2, p38MAPK,
JNKs, and CDK2 in cell response to platinum has been already
shown.17,26−28 We validated biochemically and functionally our
phosphoproteomic data on these kinases in ovarian cancer cells
(Supporting Information Figure S2).
The possible role of the PIM2 kinase in ovarian cancer cells
and in the cell response to CDDP was a novelty. The family of
PIMs29,30 consists of three highly homologous kinases (PIM1,
PIM2, and PIM3). Figure 2A shows that all three kinases are
expressed in a panel of 10 ovarian cancer cell lines,
representative of different histotypes. The treatment of ovarian
cancer cell lines with CDDP resulted in the increased
expression of at least one of the PIM kinases, with PIM2
being the most consistently increased at both the mRNA
(Figure 2B) and protein levels (Figure 2D−F), even after a
short treatment with CDDP (Figure 2C). We found that the
upregulation of PIM2 expression by CDDP was associated with
the increased phosphorylation of its substrate BAD on serine 75
(corresponding to the serine 112 of mouse bad) and serine 118
(corresponding to the serine 155 of mouse bad) (Figure 2D).
BAD phosphosites serine 118 and serine 99 were also identified
in our phosphopeptide data set as upregulated in CDDP
treated cells, as noticeable in Table 1 and Supporting
Information Table S1, respectively. Interestingly, another
DNA damaging agent, trabectedin, induced a similar increase
in PIM2 expression (Figure 2G).
Thus, we focused our attention onto the possible functional
role of PIM2 in ovarian cancer cells and first used a pan-PIM
specific biochemical inhibitor (SGI-177631). Figure 3A,B shows
that PIM inhibition resulted in reduced protein levels of c-MYC
and reduced phosphorylation of STAT3, which are among the
best characterized targets of the PIM1 and PIM2 kinases.32−34
SGI-1776 impaired the viability of ovarian cancer cells (Figure
3C) and synergized with CDDP not only in reducing cell
viability (Figure 3D) but also in inducing apoptosis, as
measured by Annexin V binding and DAPI staining (Figure
4A) and active caspase-3 staining (Figure 4B). In agreement,
pretreatment of ovarian cancer cells with SGI-1776 impaired
CDDP-triggered BAD phosphorylation (Figure 4C). A similar
effect was elicited by a structurally unrelated pan-PIM inhibitor,
CX-6258 (Figure 4D).
Silencing of PIM2 (Figure 5A,D) impaired the growth as
monolayer cultures and in semisolid medium of both SK-OV-3
(Figure 5B−C) and OVCAR-8 (Figure 5E−F) cells. Silencing
of PIM2 also showed that it was required to protect cells from
death induced by CDDP, as shown by reduced viability (Figure
6A) and increased Annexin V and DAPI staining (Figure 6B)
and PARP cleavage (Figure 6C) in PIM2-silenced cells in
comparison to that in control cells. In agreement, PIM2
silencing also impaired BAD phosphorylation triggered by
CDDP (Figure 6D).
Overexpression of PIM2 (Figure 7A) was able to protect
cells from apoptosis triggered by CDDP and trabectedin
(Figure 7B) and, accordingly, triggered BAD phosphorylation
(Figure 7A). Overexpression of PIM2 resulted per se in an
Figure 4. (A, B) Apoptotic death of the indicated ovarian cancer cell lines following exposure to CDDP for 48 h according to the drug susceptibility
of each cell line (see Experimental Procedures), evaluated as percentage of living cells labeled with neither DAPI nor AnnexinV (A) or dead cells
labeled with an active caspase-3 antibody (B); labeled cells were measured using flow cytometry. Where indicated, cells were pretreated for 3 h with
SGI-1776 (3 μM). (C) Western blot analysis showing BAD phosphorylation after CDDP treatment with or without cell pretreatment with SGI-1776
(3 μM). Cells were exposed to CDDP for 24 h according to the drug susceptibility of each cell line, as above. (D) Apoptotic death of SK-OV-3 cells
treated with CDDP (20 μM) with or without the pan-PIM inhibitor CX-6258 (2 μM) for 48 h. The blots were reprobed with vinculin antibody to
confirm equal loading. Cell viability was measured using CellTiter Glo assay. Mean ± standard deviation, n = 3. Statistical significance was
determined using ANOVA test: *P < 0.05.
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increased cell ability to form colonies in semisolid medium
(Figure 7C), in agreement with its role as a pro-oncogenic
kinase.
We queried The Cancer Genome Atlas to evaluate the status
of the PIM2 gene in ovarian cancer samples.35 Interestingly, the
PIM2 gene was amplified in a significant fraction of the 580
naiv̈e high-grade serous carcinomas of the ovary analyzed,
which was more than in any other cancer histotype (see the
Experimental Procedures for the relevant URLs).
Altogether, our data show that the PIM2 kinase is induced by
DNA damaging agents in ovarian cancer cells and might
interfere with apoptosis induced by platinum drugs likely via
regulation of BAD phosphorylation.
■ DISCUSSION
We describe here a system-wide approach to decipher
sensitivity/resistance of cancer cells to platinum. The CDDP-
regulated proteome and phosphoproteome revealed an
unexpected activation of the PIM2 kinase, not previously
identified as a factor regulated by CDDP and involved in the
cells response to the drug. This suggests that PIM2 kinase is a
potential target to sensitize cells to platinum drugs.
As expected, the top 50 CDDP-induced phosphosites include
a number of known direct targets of ATM and ATR, as also
reported in a phosphoproteomic analysis of embryonic stem
cells, i.e., cells with uncompromised DNA damage response,
treated for a short time with CDDP.5 Among them, we found
H2A.X, which is involved in the initial enzymatic processing
step of the DNA damage response. Its phosphorylation on
Ser139 is a measure of double-strand breaks (DSBs)36 and is
required for signaling the recruitment of DNA repair proteins
to DSBs. The other hyper-phosphorylated ATM substrate in
our data, the transcriptional repressor TRIM28/KAP1, plays a
key role in DNA repair when phosphorylated.24 The
upregulation of kinases involved in the MAPK (mitogen
activated protein kinase) pathway, such as ERK1/2 and
p90RSK, was also expected, as they are critical components
of the signaling network activated by CDDP.5,37 Moreover, our
Figure 5. (A, D) PIM2 knockdown to study clonogenic ability of ovarian cancer cells. PIM2 silencing at both mRNA and protein levels in SK-OV-3
(A) and OVCAR-8 (D) cells triggered by doxycycline treatment (500 ng/mL) after stable transduction with lentiviral particles carrying PIM2-
specific short hairpin (shPIM2) sequence under a Tet-on inducible promoter. Panels also show that mRNAs of PIM1 and PIM3 genes were not
affected. As a control, cells were transduced with lentiviral particles carrying a nontargeting short hairpin sequence (shScramble). Growth curves of
SK-OV-3 (B) and OVCAR-8 (E) cells after PIM2 silencing. Colony forming ability in soft-agar of SK-OV-3 (C) and OVCAR-8 (F) cells after PIM2
silencing. In this experiment, doxycycline was added every 4 days to both control (shScramble) and PIM2-silenced (shPIM2) cells for the duration of
the experiment (2 weeks for OVCAR-8 cells and 4 weeks for SK-OV-3 cells). Colonies were stained with tetrazolium salts (MTT) and counted using
ImageJ software. Statistical significance was determined using ANOVA test: *P < 0.05.
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data confirmed the activation of p38MAPK upon cell treatment
with CDDP, in accordance with our previous work,17 which is a
necessary component of the pathway controlling cell cycle
arrest and survival in p53-defective cells, such as the SK-OV-3
cells.38 Similarly, an RNAi screen of the kinome identified ATR
and its substrate CHK1 and members of the MAPK family as
the kinases mostly involved in susceptibility to CDDP of SK-
OV-3 cells.39
The bioinformatics analysis of phosphosites suggested that
PIM2 kinase is a possible target of CDDP. Biochemical data
showed that the PIM2 kinase was, indeed, induced by treating
the cells with CDDP. This was reminiscent of the PIM2
induction associated with UV-induced DNA damage.40 The
PIM proteins are a family of short-lived serine/threonine
kinases that are highly conserved throughout evolution in
multicellular organisms.29,30 In most species, this family consists
of three different members (PIM1, PIM2, and PIM3) that show
high homology and share substrate specificity. It is generally
thought that PIM kinases do not require post-translational
modifications to induce their kinase activity. They are
constitutively active,41 and their induction is largely regulated
at the transcriptional and translational levels.29,30
PIM2 is an oncogenic kinase that is overexpressed in a range
of hematopoietic malignancies and solid cancers.29,30,42,43 It has
already been shown that PIM kinases exert their oncogenic
activities in many ways, such as by phosphorylating BAD and
thus inhibiting its pro-apoptotic activity.44 On the other hand, it
has been reported that in human ovarian cancer cells
Figure 6. (A) Viability of control and PIM2-silenced cells in response to CDDP (4 μM for 48 h). Cell viability was measured with CellTiter Glo
assay (mean ± standard deviation, n = 3). In the cell viability and apoptosis assays (see below), cells were grown in the presence of doxycycline. (B)
Apoptosis assay: after CDDP treatment (10 μM for 72 h), both control and PIM2-silenced cells were labeled with Annexin V and DAPI and
analyzed by flow cytometry (left panels). The percentage of early (R7) and late (R5) apoptotic cells is indicated in the windows of a representative
experiment. The bar graph (right panel) shows the percentage of living (Annexin V and DAPI double negative) cells following the indicated
treatments (mean ± standard deviation, n = 3). (C) Western blot analysis showing PARP cleavage upon CDDP treatment (10 μM for 24 and 48 h)
in control and PIM2-silenced cells grown in the presence of doxycycline. (D) Western blot analysis showing BAD phosphorylation upon CDDP
treatment (10 μM and 20 μM for 24 h) in control and PIM2-silenced cells grown in the presence of doxycycline. The blots were reprobed with
vinculin antibody to confirm equal loading. Statistical significance was determined using ANOVA test: *P < 0.05.
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phosphorylation of BAD at serine 75 and serine 99 (known as
Ser112 and Ser136, respectively, in mouse bad) is stimulated by
CDDP and that these phosphorylation events rely on the
MAPK/ERK and PI3K/AKT signaling pathways, respectively.45
Our findings highlight the role of PIM2 kinase as a new player
contributing to the CDDP-triggered phosphorylation of human
BAD in ovarian cancer cells.
Clinically, BAD phosphorylation has been found to
determine ovarian cancer chemosensitivity and patient
survival.46 Here, we show that PIM2 kinase overexpression
partially protects ovarian cancer cells from DNA damaging
agents, likely via the induction of BAD phosphorylation, and
that targeting PIM2 by either biochemical inhibitors or RNA
interference sensitizes cells to CDDP, impairing drug-triggered
BAD phosphorylation. Moreover, the data shown here
demonstrate that the PIM2 oncogenic kinase also triggers
anchorage-independent proliferation of ovarian cancer cells.
These findings are important because some PIM kinase
inhibitors (AZD1208 and LGH447) are undergoing clinical
trials for hematological and solid cancers and several others are
under development.
We have studied the response of the SK-OV-3 ovarian cancer
cells to CDDP and validated our data in a panel of ovarian
cancer cell lines representative of different histotypes of ovarian
cancer. At diagnosis, the majority of ovarian cancer patients
present with an advanced disease and show a 5 year survival
rate of 30%. Currently, cytoreductive surgery combined with
chemotherapy based on platinum drugs and taxanes is the
Figure 7. (A) Overexpression of PIM2 and BAD phosphorylation at Ser75 in ovarian cancer cells lines. The blots were reprobed with vinculin
antibody to confirm equal loading. (B) Apoptosis assay: after either CDDP (10 μM for 72 h) or trabectedin (ET743 0.5 nM for 72 h) treatment,
both empty vector and PIM2-overexpressing cells were labeled with Annexin V and DAPI and analyzed by flow cytometry (left panel). In these
panels, the percentage of early (R7) and late (R5) apoptotic cells are indicated in the windows of a representative experiment. The bar graph (right
panel) shows the percentage of living (Annexin V and DAPI double negative) cells following the indicated treatments (mean ± standard deviation, n
= 3). (C) Graph showing the number of colonies formed by empty-vector and PIM2-overexpressing SK-OV-3 cells grown for 40 days in semisolid
medium (soft-agar assay) both in the presence or in the absence of CDDP (5 μM). Colonies were stained with tetrazolium salts (MTT) and counted
using ImageJ software. Statistical significance was determined using ANOVA test: *P < 0.05.
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standard treatment. Approximately 70% of patients respond to
first-line chemotherapy, with the others being inherently
platinum refractory. Moreover, approximately 70% of plati-
num-sensitive patients develop resistance later, suffer recur-
rence of disease, and eventually die. Therefore, the most critical
issues in the therapy of advanced ovarian cancer are primary
and acquired resistance to platinum-based treatments.
■ CONCLUSIONS
We provide the first quantitative and global phosphoproteomic
analysis of an ovarian cancer cell line exposed to a platinum
compound. This led to the identification of PIM2 as a
candidate target kinase, predicted by contextual analysis of
phosphosites. Functional validation showed that, in a number
of ovarian cancer cell lines, PIM2 is involved in controlling cell
growth and survival and response to DNA-damaging chemo-
therapeutics. Importantly, the PIM kinases are druggable and
clinically viable inhibitors that are undergoing trials. Therefore,
PIM kinase target therapy is a potential avenue to improve
platinum sensitivity and to reverse resistance to platinum.
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